

"Express Mail" mailing label number : EL 984 914 764 US

Date of Deposit : October 28, 2003

Type of Documents : Information Disclosure Statement (2 pages);

Form PTO-1449 (5 pages) and References:

13 US Patents;10 Foreign Patents;78 Other Documents

Return Postcard

Serial No. : 10/607,930

Filing Date: : June 27, 2003

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and are addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Diane H. Marshall (signature)

OCT 2 8 2003

## N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Bhatti, et al. : Examiner: To be assigned

Serial No.: 10/607,930 : Art Unit: 1614

Filed: June 27, 2003 : Docket No.: T103 1530.1

For: N-Aryl Diazaspiracyclic Compounds and Methods

of Preparation and Use Thereof

## **INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants hereby voluntarily disclose the documents listed on the attached Form PTO-1449 to the Assistant Commissioner for Patents. This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits of the application. Accordingly, it is believed that no fees are due. However, should any fees be due, the Patent Office is hereby authorized to charge Deposit Account No. **09-0528**. A duplicate sheet is enclosed for this purpose.

Document F3 (EP 0 417 631 A2) is a copy of the published European Patent Application (German language only). Document D78, a bibliographic printout from DELPHION research service, containing an English language abstract apparently prepared by the DERWENT company. The abstract appears to suggest that the document comprises a discussion of condensed diazepinones of the general formula I (see published European patent application for formula I), having the substituents are recited therein. The document apparently alleges that such compounds are suitable for the therapy or cholinergically related spasms and motility disturbances in the gastrointestinal tract, in the billiary tract, for the symptomatic therapy of cystitis and of spasms associated with urolithiasis, for the therapy of relative incontinence, for the symptomatic therapy of bronchial asthma and of bronchitis, and for the therapy of ischaemic heart diseases.

Appln No. 10/607,930 EL 984 914 764 US

The document D66 (Süess, Rudolf, "Regiospezifische Reduktionen von 1,3,3-trisubstituierten Succinimiden mit Diboran," *Helv. Chim. Acta* 60: 1650-1656 (1977)), in the German language, was published with an English abstract that appears to indicate that the document discusses the regiospecific reduction of 1,3,3-trisubstituted succinimides by diborane.

The document D67 (Sury, et al., "Über Alkylenimin-Derivate. Beitrag zur Kenntnis der Diaza-spiro-undecane," Helv. Chim. Acta 36: 1815-1820 (1953)) in the German language, appears to indicate that the document discusses procedures for the preparation of diaza-spiro-undecanes.

Copies of one hundred one (101) documents are enclosed. Applicants further reserve the right to establish the patentability of the claimed invention over any of the listed information should they be applied as documents, and/or to prove that the cited information may not be prior art, and/or to prove that the cited information may not be enabling for the teachings they purport to offer. This statement further should not be construed as the representation that any search has been made, or that the information cited herewith is material, or that there does not exist information more material to the examination of the present Application. The Examiner is specifically requested not to rely solely on the information submitted herein. On the contrary, the Examiner is requested to conduct an independent and thorough review of all available information, and to form independent opinions as to its significance.

It is respectfully requested that the Examiner initial and return copies of the enclosed PTO-1449 and to indicate in the official file wrapper of the above-identified patent application that each item of the cited information has been considered.

Respectfully submitted,

Date: ()ct 27, 2003

Carl B. Massey, Jr.

Registration No. 44,224 Attorney for Applicants

Docket: T103 1530.1

Womble Carlyle Sandridge & Rice, PLLC Post Office Box 7037 Atlanta, Georgia 30357-00378 Telephone (336) 721-3681 Facsimile(336) 726-8074 FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY DKT NO. SERIAL NO. PATENT AND TRADEMARK OFFICE 10/607,930 T103 1530.1 **APPLICANT** OCT 2 8 2003 Bhatti, et al. ANFORMATION DISCLOSURE FILING DATE **GROUP** 06-27-03 1614 STATEMENT BY APPLICANT U.S. PATENT DOCUMENTS **EXAMINER** FILING DATE **DOCUMENT DATE** SUBCL. **NAME** CL. IF APPROP. **INITIAL** NO. 3,282,947 11/1966 Grogan, et al. 293 **P**1 260 P2 05/1990 203.26 4,922,901 Brooks, et al. 128 Kikuchi, et al. 249 P3 5,187,166 02/1993 514 299 5,583,140 12/1996 514 Bencherif, et al. **P4** P5 5,597,919 01/1997 544 242 Dull, et al. 514 256 **P6** 5,604,231 02/1997 Smith, et al. Dull, et al. 546 300 **P**7 5,616,716 04/1997 P8 5,663,356 09/1997 Ruecroft, et al. 300 546 P9 5,672,601 09/1997 Cignarella 249 514 P10 5,733,912 03/1998 Wasicak, et al. 514 253 5,852,041 12/1998 Cosford, et al. 514 351 P11 P12 02/2000 Olesen, et al. 6,022,868 514 210 Czollner, et al. 514 217.01 P13 US 2003/ 05/2003 0092700 FOREIGN PATENT DOCUMENTS TRANSLATION **DOCUMENT** CL. **SUBCL DATE COUNTRY** NO. YES NO F1 01/1989 EP EP 0 297 858 <sub>4</sub> F2 EP 0 360 390 : 03/1990 EP F3 EP 0 417 631 03/1991 EP GB 2 295 387 05/1996 F4 GB WO WO 94/08992 4/1994 F5 WO 96/31475 / 10/1996 WO **F6** 12/1996 WO 96/40682, WO F7 WO 97/40049 · WO (See published English F8 10/1997 language related application P13 above) WO 06/1998 F9 WO 98/25619 WO 99/21834 -05/1999 WO F10 **EXAMINER DATE CONSIDERED** 

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not

in conformance and not considered. Include copy of this form with next communication to applicant.

| EORM PO     | 0-1449 | U.S. DEPARTMENT OF COMMERCE  | ATTY DKT NO.             | SERIAL NO.                 |  |  |
|-------------|--------|--|--------------------------|----------------------------|--|--|
| 0           |        | PATENT AND TRADEMARK OFFICE  | T103 1530.1              | 10/607,930                 |  |  |
| <b>/</b>    | (3)    |  | APPLICANT                | 10/00/3550                 |  |  |
| 007 2 8 201 | 03 (c) |  | Bhatti, et al.           |                            |  |  |
| 77,         |        | NFORMATION DISCLOSURE  | FILING DATE              | GROUP                      |  |  |
| 通           | 7.7    | STATEMENT BY APPLICANT   | 06-27-03                 | 1614                       |  |  |
| OTHERADO    |        | NTS (Incl. Author, Title, Date, Pertinent pages, etc.)   | <u> </u>                 |                            |  |  |
| D           |        | Abramovitch, R.A., editor, "Pyridine and Its Derivatives," Su  | pp. Part Three, pp. 3-5. | in Chemistry of            |  |  |
| ļ           | _      | Heterocyclic Compounds, Volume 14 (Interscience Publisher  |                          |                            |  |  |
| D           | 02     | Adamcik, J.A., and E.J. Miklasiewicz, "Cyanoethylation. I. Weakly Basic Catalysts in the Reaction of Acrylonitrile with Active Methylene Compounds," <i>J. Org. Chem.</i> 28: 336-339 (1963).              |                          |                            |  |  |
| D           | 93     | Arneric, S., et al., "Preclinical Pharmacology of ABT-418: A Prototypical Cholinergic Channel Activator for the Potential Treatment of Alzheimer's Disease," CNS Drug Rev., 1(1): 1-26 (1995).             |                          |                            |  |  |
| D           | 04     | Arneric, S.P., et al., "Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease," Exp. Opin. Invest. Drugs, 5(1): 79-100 (1996).  |                          |                            |  |  |
| D           | )5     | Bannon, A.W., et al., "Broad-Spectrum, Non-Opioid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors," Science, 279: 77-81 (1998).                                   |                          |                            |  |  |
| D           | 06     | Bencherif, M., et al., "RJR-2403: A Nicotinic Agonist with CNS Selectivity I: In Vitro Characterization," Pharmacol. Exper. Therapeutics, 279(3): 1413-1421 (1996).  |                          |                            |  |  |
| D           | 7      | Berkowitz, D.B., and M.K. Smith, "Enantiomerically Enriched α-Methyl Amino Acids. Use of an Acyclic Chiral Alanine-Derived Dianion with a High Diastereofacial Bias," J. Org. Chem., 60: 1233-1238 (1995). |                          |                            |  |  |
| D           | 8      | Brioni, J.D., et al., "The Pharmacology of (-)-Nicotine and Novel Cholinergic Channel Modulators," Adv. Pharmacol., 37: 153-215 (1997).  |                          |                            |  |  |
| D           | 9      | Burger, A., et al., "Some Derivatives of Tetrahydropyran as P Soc., 72: 5512-5515 (1950).  | Potential Pharmacodyna   | mic Agents," J. Am. Chem.  |  |  |
| D           | 10     | Cheng, Y., and W.H. Prusoff, "Relationship Between the Inhi<br>Inhibitor which Causes 50 Per Cent inhibition (I <sub>50</sub> ) of an Enzy<br>3099-3108 (1973).  | ,                        |                            |  |  |
| D           | 11     | Chiari, A., et al., "Sex Differences in Cholinergic Analgesia I Females," Anesthesiology, 91(5): 1447-1454 (1999).   | : A Supplemental Nicot   | tinic Mechanism in Normal  |  |  |
| D           | 12     | Ciblat, S., et al., "A new route to 2-spiropiperidines," Tet. Let  | t., 42: 4815-4817 (2001  | ).                         |  |  |
| D           | 13     | Clarke, K., and K. Rothwell, "A Kinetic Study of the Effect of Alkylpyridinium Halides in Nitromethane Solution," J. Chem.   |                          |                            |  |  |
| D           | 14     | Comins, D.L, and M.O. Killpack, "Lithiation of Methoxypyri Chem., 55(1): 69-73 (1990).   | dines Directed by α-An   | nino Alkoxides," J. Org.   |  |  |
| D           | 15     | Cosford, N.D.P., et al., "(S)-(—) 5- Ethynyl-3-(1-methyl-2-py Novel Anti-Parkinsonian Agent with Selectivity for Neuronal Chem., 39(17): 3235-3237 (1996).   | * · <b>~</b> •           | •                          |  |  |
| D           | 16     | Culbertson, T.P., et al., "Quinolone Antibacterial Agents Subsynthesis and Structure-Activity Relationships," J. Med. Cher.  |                          | •                          |  |  |
| D           | 17     | Damaj, M.I., et al., "Analgesic Activity of Metanicotine, A Son Neuroscience, 23: 669 ABSTRACT 266.9 (1997).   |                          |                            |  |  |
| D           | 18     | Damaj, M.I., et al., "Antinociceptive and Pharmacological Ef Agonist," J. Pharmacol. Exp. Ther., 291(1): 390-398 (1999).   | fects of Metanicotine, a | Selective Nicotinic        |  |  |
| D           | 19     | Decina, P., et al., "Cigarette Smoking and Neuroleptic-Induce (1990).  | ed Parkinsonism," Biol.  | Psychiatry, 28(6): 502-508 |  |  |
| D           | 20     | Elliott, J.M., et al., "Serine Derived NK1 Antagonists 2: A Ph Binding," Bioorg. Med. Chem. Lett., 8: 1851-1856 (1998).  | narmacophore Model fo    | r Arylsulfonamide          |  |  |
| D           | 21     | Fornicola, R.S., et al., "A New Synthesis of α-Amino Acid D Versatile Glycine Template," J. Org. Chem., 63(11): 3528-35  |                          | Methyl Nitroacetate as a   |  |  |
| D           | 22     | Genin, M.J., et al., "Synthesis and Crystal Structure of a Pept<br>Type-II β-Turn Mimic," J. Org. Chem., 58(8): 2334-2237 (19  | idomimetic Containing    | the (R)-4.4-Spiro Lactam   |  |  |
| D           | 23     | Genin, M.J., and R.L. Johnson, "Design, Synthesis, and Confe   | ormational Analysis of   |                            |  |  |
| D           | 023    | Genin, M.J., and R.L. Johnson, "Design, Synthesis, and Confe<br>System as a Type II β-Turn Peptidomimetic," J. Amer. Chem.   | •                        | •                          |  |  |

| FADIM DTO 144 | O II C DEDADTMENT OF COMMEDCE  | ATTY DKT NO.                       | SEDIAL NO                          |
|---------------|--|------------------------------------|------------------------------------|
| FORM PTO-144  | 9 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  | T103 1530.1                        | SERIAL NO.<br>10/607,930           |
| (c)           | INIDITAND NADDIMAN OFFICE  | APPLICANT                          | 10/00/,730                         |
| S 2000        |  | Bhatti, et al.                     |                                    |
| OCT 2 8 2003  | INFORMATION DISCLOSURE   | FILING DATE                        | GROUP                              |
| EE            | STATEMENT BY APPLICANT   | 06-27-03                           | 1614                               |
| F TRADEN AD24 | Gibson, S., et al., "Principal Components Describing Biologic  | cal Activities and Mole            | cular Diversity of                 |
| ADEN          | Heterocyclic Aromatic Ring Fragments," J. Med. Chem., 39(2)  |                                    | •                                  |
| D25           | Grogan, C.H., et al. "Spiranes. VII. Neuroleptics Derived from the second secon |                                    |                                    |
| D26           | Hall, G.H., and D.M. Turner, "Effects of Nicotine on the Rele  | ease of <sup>3</sup> H-Noradrenali | ne from the Hypothalamus,          |
|               | Biochemical Pharmacology, 21: 1829-1838 (1972).  |                                    |                                    |
| D27           | Hamon, M., "Neuropharmacology of anxiety: perspectives an  |                                    |                                    |
| D28           | Hansch, C., et al., "The Parabolic Dependence of Drug Action Study of Hypnotics," J. Med. Chem., 11(1): 1-11 (1967).   |                                    |                                    |
| D29           | Hansch, C., et al., "A Survey of Hammett Substituent Constant Rev., 91(2): 165-195 (1991).   | nts and Resonance and              | Field Parameters," Chem.           |
| D30           | Hansen, M.M., et al., "An Enantioselective Synthesis of Cis I 63(3): 775-785 (1998).   | Perhydroisoquinoline L             | Y235959," J. Org. Chem.,           |
| D31           | Harsing, Jr., L.G., et al., "Dopamine Efflux from Striatum Af Desensitization," J. Neurochem., 59(1): 48-54 (1992).  | ter Chronic Nicotine: E            | vidence for Autoreceptor           |
| D32           | Hartwig, J.F., et al., "Room-Temperature Palladium-Catalyze  | •                                  |                                    |
|               | Extended Scope of Aromatic C—N Bond Formation with a Co 5580 (1999).   | ommerical Ligand," J.              | Org. Chem., 64(15): 5575-          |
| D33           | Hertog, H.J.D., et al., "The Directive Influence of the N-Oxide Pyridine N-Oxide (IV) 1) Nitration of 3-bromo-5methoxy- and  |                                    |                                    |
|               | Trav. Chim. Pays-Bas, 74(8/9): 1171-1179 (1955).   |                                    |                                    |
| D34           | Hery, F., et al., "Control of the Release of Newly Synthetized Muscarinic Receptors in Rat Hypothalamic Slices," <i>Naunyn-S</i> (1977).   |                                    | •                                  |
| D35           | Hinds, M.G., et al., "Synthesis, Conformational Properties, an β-Turn Mimetics Based on α-Alkylproline Derivatives," J. M.   | •                                  | •                                  |
| D36           | Hoffman, J.M., et al., "Synthesis and Evaluation of 2-Pyridin<br>Transcriptase Inhibitors. 4. 3-[2-(Benzoxazol-2-yl)ethyl]-5-6<br>J. Med. Chem., 36(8): 953-966 (1993).  |                                    | -                                  |
| D37           | Holladay, M.W., et al., "Neuronal Nicotinic Acetylcholine Re<br>Chem, 40(26): 4169-4194 (1997).  | eceptors as Targets for            | Drug Discovery," J. Med.           |
| D38           | Holland, A. et al., "Isothiazoles. Part IX. Isothiazolopyrimid   | ines," J. Chem. Soc., 72           | 277-7282 (1965).                   |
| D39           | Hughes, D.L., "The Mitsunobu Reaction," Org. React., 42: 33  | 35-657 (1992).                     |                                    |
| D40           | Hughes, D.L., "Progress in the Mitsunobu Reaction. A Review (1996).  | w," Org. Prep. Proced              | I. Int., 28(1): 129-164            |
| . D41         | Islam, A.M., and R.A. Raphael, "A Direct Transformation of ones," J. Chem. Soc., 3151-3154 (1955).   | cycloHexanones into b              | icyclo [5: 3: 0] <i>Dec-7-en-9</i> |
| D42           | Kim, K., et al., "Novel Bicyclic Lactams as XaaPro Type VI Evaluation," J. Org. Chem., 61(9): 3138-3144 (1996).  | β Turn Mimics: Design              | n, Synthesis and                   |
| D43           | Lall, M.S., et al., "Serine and Threonine β-Lactones: A New Inhibitors," J. Org. Chem., 67(5): 1536-1547 (2002).   | Class of Hepatitis A V             | irus 3C Cysteine Proteinas         |
| D44           | Latli, B., et al., "Novel and Potent 6-Chloro-3-pyridinyl Ligar<br>Receptor," J. Med. Chem., 42(12): 2227-2234 (1999).   | nds for the α4β2 Neuro             | onal Nicotnic Acetylcholine        |
| D45           | Lavand'homme, P., and J.C. Eisenach, "Sex Differences in C<br>Two Models of Allodynia," <i>Anesthesiology</i> , 91(5): 1455-146  |                                    | : Differing Mechanisms in          |
| D46           | Lippiello, P.M., et al., "RJR-2403: A Nicotinic Agonist with E. T., 279(3): 1422-1429 (1996).  |                                    | Vivo Characterization," J. I       |
| D47           | Majer, Z., et al., "Synthesis and Absolute Configuration of 1, Chem. Comm., 47(3): 950-960 (1982).   | 7 Diazaspiro[4,4]Nona              | ne-2,6-Dione," Coll. Czech         |
| D48           | Old, D.W., et al., "A Highly Active Catalyst for Palladium-C. Temperature Suzuki Couplings and Amination of Unactivated 9722-9723 (1998).  |                                    |                                    |

| EODM DT  | 0 144 | II S DEDADTMENT OF COMMEDCE   | ATTY DKT NO.              | SERIAL NO.                       |  |  |
|--|-------|---|---------------------------|----------------------------------|--|--|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  |       |   | T103 1530.1               | 10/607,930                       |  |  |
| O P E PATENT AND TRADEMARK OFFICE  |       |   | APPLICANT 10/007,930      |                                  |  |  |
|  | 6     |   | Bhatti, et al.            |                                  |  |  |
|  | 03    | NFORMATION DISCLOSURE   | FILING DATE               | GROUP                            |  |  |
| OCT 2 8 2003   | ta:   | STATEMENT BY APPLICANT  | 06-27-03                  | 1614                             |  |  |
| D Cod  | 1497  | Onaivi, E.S., et al., "Chronic Nicotine Reverses Age-Associated Increases in Tail-Flick Latency and Anx Rats," Life Sciences, 54(3): 193-202 (1994).  |                           |                                  |  |  |
| D  | 050   | Overberger, et al., "Absolute Configuration of 2,7 Diazaspiro 46(13): 2757-2764 (1981)  | o[4.4]nonane. A Reassi    | gnment," J. Org. Chem.,          |  |  |
| D  | 051   | Overman, L.E., and R.M. Burk, "A Convenient Synthesis of Unsymmetrical Secondary Amines. <u>In Situ</u> Formation of Unstable Formaldehyde Imines," <i>Tet. Lett.</i> , 25(16): 1635-1638 (1984).  Pedersen, M.L., and D.B. Berkowitz, "Formal α-Vinylation of Amino Acids. Use of a New Benzeneselenol Equivalent," <i>J. Org. Chem.</i> , 58(25): 6966-6975 (1993). |                           |                                  |  |  |
| D  | 052   |   |                           |                                  |  |  |
| D  | 053   | Pomerleau, O.F., et al., "The Effects of Cigarette Smoking on Pain and Anxiety," Addictive Behaviors, 9: 26: 271 (1984).  |                           |                                  |  |  |
| D  | 054   | Pullan, R.D., et al. "Transdermal Nicotine for Active Ulcerative Colitis," New England J. Med., 330(12): 811-815 (1994).  |                           |                                  |  |  |
| D55 Radziszewski, J.G., et al., "Twisted Si=N Bonds: Matrix Isolation of Bridgehead Silanimines," J Soc., 115(18): 8401-8408 (1993). |       |   |                           |                                  |  |  |
| D  | 056   | Ranganathan, D., et al., "Nitroethylene: A Stable, Clean, and Chem., 45(7): 1185-1189 (1980).   | d Reactive Agent for Or   | ganic Synthesis," J. Org.        |  |  |
| D  | 057   | Rapier, C., et al., "Stereoselective Nicotine-Induced Release Concentration Dependence and Repetitive Stimulation," J. N  | <del>-</del>              | -                                |  |  |
| D  | 058   | Reiter, L.A., "Synthesis of 4(5)-Acyl-, 1-Substituted 5-Acyl-Aminosioxazoles," J. Org. Chem., 52(13): 2714-2726 (1987)  | , and 1-Substituted 4-A   |                                  |  |  |
| D  | 59    | Ricciardi, F.J., and P.H. Doukas, "Facile Synthesis of Styrlqu  |                           | cles, 24(4): 971-977 (1986).     |  |  |
| D  | 060   | Rice, L.M., et al., "Spiranes. V(1) A Synthetic Route to Synundecanes," J. Het. Chem., 1(3): 125-127 (1964).  |                           |                                  |  |  |
| D  | 061   | Rowell, P.P. and D.L. Winkler, "Nicotinic Stimulation of [3 I Cortical Synaptosomes," J. Neurochem., 43(6): 1593-1598 (1  | _                         | se from Mouse Cerebral           |  |  |
| D  | 062   | Sanberg, P.R., et al., "Nicotine Potentiation of Haloperidol-In Pharmacol. Biochem. & Behavior, 46: 303-307 (1993).   |                           | atal Mechanisms,"                |  |  |
| D  | 063   | Sandor, N.T., et al. "Effect of nicotine on dopaminergic-chol 313-316 (1991).   | inergic interaction in th | e striatum," Brain Res., 567     |  |  |
| D  | 064   | Selnick, H.G., et al., "Preparation and Trapping of 3-Lithium (1993).   | -O-Lithiophenoxide," 7    | Tet. Lett., 34(13): 2043-2046    |  |  |
| D  | 065   | Smith, P.W., et al., "New Spiropiperidines as Potent and Sele Antagonists," J. Med. Chem., 38(19): 3772-3779 (1995).  | ective Non-Peptide Tac    | hykinin NK <sub>2</sub> Receptor |  |  |
| D  | 066   | Süess, R. and A.G. Sandoz, "Regiospezifische Reduktionen Diboran," Helv. Chim. Acta, 60: 1650-1656 (1977).  | von 1,3,3-trisubstituiert | en Succinimiden mit              |  |  |
| D  | 067   | Sury, E., and K. Hoffmann, "Über Alkylenimin-Derivate. Be Chim. Acta, 36: 1815-1820 (1953).   | itrag zur Kenntnis der I  | Diaza-spiro-undecane," Helv      |  |  |
| D  | 068   | Thomas, J. and D. Clough, "The Preparation and Measureme 1,1'-Spirobipiperidinium Bromides," J. Pharm. Pharmacol.,  |                           | -                                |  |  |
| D  | 069   | Toth, E., et al., "Effect of Nicotine of Extracellular Levels of Various Brain Regions: Role of Glutamic Acid," Neurochem   | Neurotransmitters Asse    | essed by Microdialysis in        |  |  |
| D  | 70    | Tripathi, H.L., et al., "Nicotine-Induced Antinociception of F<br>Levels," J. Pharmacol. Exp. Ther., 221(1): 91-96 (1982).  |                           |                                  |  |  |
| D  | 071   | Vizi, E.S., "Acetylcholine release from guinea-pig ileum by like polypeptides," <i>Br. J. Pharmac.</i> , 47: 765-777 (1973).  | parasympathetic ganglic   | on stimulants and gastrin-       |  |  |
| D  | )72   | Wagaw, S. and S.L. Buchwald, "The Synthesis of Aminopyr Carbon-Nitrogen Bond Formation," J. Org. Chem., 61(21):   |                           | loying Palladium-Catalyzed       |  |  |
| D  | 073   | Wagner, B., et al., "Does Smoking Reduce the Risk of Neuro 302-303 (1988).  | oleptic Parkinsonoids?,"  | 'Pharmacopsychiat., 21:          |  |  |

| PATENT AND TRADEMARK OFFICE T103 1530.1 10/607,930 APPLICANT  |  |  |  |  |  |
|---|--|--|--|--|--|
| APPLICANT   |  |  |  |  |  |
|   |  |  |  |  |  |
| Bhatti, et al.  | Bhatti, et al.   |  |  |  |  |
| OCT 2 8 2003 LINFORMATION DISCLOSURE FILING DATE GROUP  |  |  |  |  |  |
| STATEMENT BY APPLICANT 06-27-03 1614  |  |  |  |  |  |
| D749 Wittekind, R.R., and C. Weissman, "Synthesis of the 1,8-Diazaspiro [4.5] decane System," J. Het. Chem., 9 111-113 (1972).  | (1):   |  |  |  |  |
| D75 Williams, M., et al., "Neuronal Nicotinic Acetylcholine Receptors," Drug News Perspec., 7(4): 205-223 (1  |  |  |  |  |  |
|   | Zhu, J., et al. "Asymmetric Synthesis. 29. Preparation of 1,8-Diazaspiro [5.5] undecane Derivatives," J. Org.  |  |  |  |  |
| D77 Zwart, C., and J.P. Wibaut, "Chemical Behaviour of 3-Aminopyridine and of 3,5-Diaminopyridine. Synthetics of (3-Pyridyl)-Pyrazolones." <i>Recueil Trav. Chim. Pays-Bas</i> , 74(8/9): 1062-1069 (1955). | Zwart, C., and J.P. Wibaut, "Chemical Behaviour of 3-Aminopyridine and of 3,5-Diaminopyridine. Syntheses of (3-Pyridyl)-Pyrazolones." <i>Recueil Trav. Chim. Pays-Bas</i> , 74(8/9): 1062-1069 (1955). |  |  |  |  |
| D78 Delphion Printout – Bibliographic Data for EP 0417 631 A2 (Document F3) shows Derwent English langu abstract. Oct. 21, 2003.  | Delphion Printout – Bibliographic Data for EP 0417 631 A2 (Document F3) shows Derwent English language abstract. Oct. 21, 2003.  |  |  |  |  |
|   |  |  |  |  |  |
|   |  |  |  |  |  |
|   |  |  |  |  |  |
|   | _  |  |  |  |  |
|   |  |  |  |  |  |
|   |  |  |  |  |  |
|   |  |  |  |  |  |
|   |  |  |  |  |  |
|   |  |  |  |  |  |
|   |  |  |  |  |  |
| EXAMINER DATE CONSIDERED  |  |  |  |  |  |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.